Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF).
about
Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leakyThe angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritisDisease-modifying activity of SB 273005, an orally active, nonpeptide alphavbeta3 (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis.Quantitation of the changes in vascularity during arthritis in the knee joint of a mouse with a digital image analysis system.The Immunomodulatory Effect of Trichophyton Rubrum Exoantigens in the Treatment of Experimental Septic Arthritis.New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders.The role of angiogenesis in rheumatoid arthritis: recent developmentsNew therapies in development for autoimmune diseases: their rationale for combination treatment.Antagonising angiogenesis in rheumatoid arthritisVEGF and imaging of vessels in rheumatoid arthritisQuantitative assessment of the rheumatoid synovial microvascular bed by gadolinium-DTPA enhanced magnetic resonance imaging.Angiogenesis as a target in rheumatoid arthritis.Endogenous regulation of angiogenesis in the rat aorta model. Role of vascular endothelial growth factor.Neoangiogenesis contributes to the development of hemophilic synovitis.Drugs to suppress cough.Cellular response to tissue hypoxia and its involvement in disease progression.CD40-induced signaling in human endothelial cells results in mTORC2- and Akt-dependent expression of vascular endothelial growth factor in vitro and in vivoMethionine aminopeptidase-2 blockade reduces chronic collagen-induced arthritis: potential role for angiogenesis inhibition.The immunopharmacologic potential of Semaxanib and new generation directed therapeutic drugs: Receptor tyrosine kinase regulation with anti-tumorigenensis/angiogenesis properties.Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritisTemporal cytokine expression and the target organ attributes unravel novel aspects of autoimmune arthritis.Overexpression of vascular endothelial growth factor and the development of post-transplantation cancerDesign of a new line in treatment of experimental rheumatoid arthritis by artesunate.Artemether: a new therapeutic strategy in experimental rheumatoid arthritis.Regulation of VEGF mRNA expression and protein secretion by TGF-beta2 in human retinal pigment epithelial cells.Cyclosporine inhibition of vascular endothelial growth factor production in rheumatoid synovial fibroblasts.Adenoviral delivery of soluble VEGF receptor 1 (sFlt-1) abrogates disease activity in murine collagen-induced arthritis.Adenovirus-mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis.Tuftsin binds neuropilin-1 through a sequence similar to that encoded by exon 8 of vascular endothelial growth factor.Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.Synovial concentrations of the angiogenic peptides bFGF and VEGF do not discriminate rheumatoid arthritis from other forms of inflammatory arthritis.Suppression of collagen-induced arthritis in rats by continuous administration of dae-bang-poong-tang (da-fang-feng-tang).
P2860
Q24793680-0A545A61-E19C-499D-B30B-E26471A2CBA5Q24795972-20773E23-C74A-45F4-832A-222F2BA94617Q32044975-43E39B8C-D3E7-4B55-9241-14CC0222E907Q33181831-59BBE406-913A-47C2-9AE5-235D4166FEE5Q33795163-9AA1A240-07BA-4CEF-8069-39EC405525CCQ33801264-F938FEA8-2E48-453E-96EE-DC1D0A8EA5B2Q34071300-AB4E5107-7D94-43F4-AD90-33CC8C7473FFQ34309745-4758B3FE-5916-43F4-8DD6-CD33244DFE41Q34560589-A6DB75C5-98D6-411E-BD5E-7DD5E05AA6A8Q34731141-78C9B6AA-7D48-4D46-9B2A-EB77744C97CAQ35547725-6D35BCD5-4A62-4C56-9098-5BE99F6EF757Q35553507-0AE97254-D7B4-4622-BE95-00D80B033E9BQ35764062-AC54146B-1EEE-4E24-B002-AB136A0F8082Q35866182-43F1B7C8-7707-4F35-9A24-4B658AC83573Q36040853-06B41293-910D-4065-A7CB-6D114757A1E1Q36268487-69A72A02-2A9C-4CD6-A61E-BE491B69820FQ36392591-5F26A069-AA1C-4B7F-9A94-B6C0F8DACE6BQ36465519-1A5D457B-6F45-49A9-8991-467852E4E2F1Q37098747-31BD3BC4-2A53-49AC-969D-6A7DD342D26CQ37229283-712CAFC4-CC2C-461B-A827-AC09CD250DAFQ38179171-DC0DB378-8E96-48DD-A491-55B1FABBBD8AQ39960762-4E002E5B-346E-4AD3-AF0E-49318CE6481EQ40228242-FCA1F95E-3493-41C4-AB35-7A9C4A911D09Q40325293-F68A187F-B720-486F-B7E4-67086A5CA0CBQ42509034-FE414C62-BC46-430B-9FF6-F8C5A9A31424Q44062273-0861E08E-0204-40F8-B900-314CE7868C8EQ44301754-91E4465E-0E78-4A20-A440-EE7B7D0BE9DFQ45883663-B934FFB5-08A8-435A-A6D8-6D39DD957CEAQ46863316-108D735C-3AF9-488D-BA57-60892E469791Q47849220-7AC9F5DA-3BE2-4984-B225-A31382558CC4Q47941172-32F68B3C-43E8-490D-BA00-71178A0E0E00Q50503842-5AC60B7C-BDFA-4BC8-83E5-79884063F1B4
P2860
Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF).
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh-hant
name
Suppression of collagen-induce ...... othelial growth factor (VEGF).
@en
Suppression of collagen-induce ...... othelial growth factor (VEGF).
@nl
type
label
Suppression of collagen-induce ...... othelial growth factor (VEGF).
@en
Suppression of collagen-induce ...... othelial growth factor (VEGF).
@nl
prefLabel
Suppression of collagen-induce ...... othelial growth factor (VEGF).
@en
Suppression of collagen-induce ...... othelial growth factor (VEGF).
@nl
P2093
P356
P1433
P1476
Suppression of collagen-induce ...... othelial growth factor (VEGF).
@en
P2093
M L Banquerigo
S J Oliver
P304
P356
10.1006/CIMM.1995.9978
P577
1995-12-01T00:00:00Z